News
Merck is shifting manufacturing for its blockbuster drug Keytruda to a new $1 billion factory in Delaware, doubling down on ...
Devoted Health shows growth in 2024 with increased membership and revenue while reducing operating losses, contrasting with ...
Abeona Therapeutics received FDA approval for its cell therapy to treat “butterfly skin,” a rare genetic disease that causes ...
Eli Lilly partners with Creyon Bio in $13M upfront deal, potential $1B+ milestone payments. CEO Serge Messerlian leads ...
Venture-backed Devoted Health seems to be weathering the Medicare Advantage storm, according to an Endpoints News analysis of ...
Novartis reports strong Q1 2025 with $13.2B in sales, beating forecasts. Key drugs Xolair, Zolgensma, Kisqali exceed ...
Pfizer is expanding its multibillion-dollar cost-cutting effort that began in 2023, announcing $1.7 billion in new planned ...
AstraZeneca and Novartis emphasize US manufacturing capacity to avoid potential pharma tariffs, with Novartis aiming for 100% ...
AstraZeneca said it was shutting down a Phase 3 Truqap study in a hard-to-treat form of prostate cancer after an interim ...
Basil Systems uses AI to help multinational companies like Johnson & Johnson, Bayer, 3M and Medtronic navigate regulations.
In an unlikely partnership between two rivals, Hims & Hers said its members will now be able to get Novo Nordisk’s weight ...
Octagon Therapeutics, led by CEO Isaac Stoner, is shutting down after halting work on B cell immunomodulator and facing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results